【摘要】 目的：观察小剂量血脂康、普伐他汀对高血脂病人的长期调脂作用。方法：多中心，195例高血脂病人，分血脂康组每晚睡前口服血脂康2粒（含他汀类物质6mg）与普伐他汀组（每晚睡前口服5mg）治疗6个月，比较治疗前、后血脂水平变化及两组间差异，用方差分析法检验及X2检验。结果：血脂康与普伐他汀治疗6个月时，TC下降16%及17%，TG下降13%及15%，LDL下降23%及21%；HDL在血脂康组上升2%，在普伐他汀组上升10%。两组均能有效降低LDL/HDL。两组间比较普伐他汀升HDL作用较血脂康稍好（P=0.05）。两组TC、LDL、LDL/HDL下降均有统计学意义。两组TG下降及HDL升高无统计学意义，血脂康及普伐他汀组降TC疗效分别为54.6%、68.4%；升HDL疗效分别为49.1%、53.9%；降TG为46.2%、40.8%。两组疗效差异均无显著性。两组均未见严重副作用。结论：小剂量他汀类药物（如血脂康和普伐他汀）长期口服治疗成人血脂紊乱，安全、有效。更多还原

【Abstract】 Objective To compare the effects of low-dose Xuezhikang with that of Pravastatin for long-term therapy on Chinese patients with dyslipidemia. Methods One hundred and ninety-five cases from six hospitals in Beijing were studied by being randomly divided into two groups and given Xuezhikang 2 capsules QN and Pravastatin 5 mg QN respectively for 6 months. The levels of TC, TG, LDL-C and HDL-C in pre- and post-treatment for each group were analyzed. The differences between the two groups were compared using ANOVA. The efficacy-rates for lowering TC, TG and increasing HDL-C of each group were calculated according to "The Guidline to Clinical Drug Research" and the differences between the two groups were compared with X2 test. Results Comparing with pre-treatment the TC decreased 16% and 17%, TG decreased 13% and 15%, LDL-C decreased 23% and 21%, HDL-C increased 2% and 10% after administering for 6 months in Xuezhikang and Pravastatin groups respectively. Both of the drugs could decrease LDL/HDL effectively as well. The decreases of TC, TG, LDL-C, and LDL/HDL were statistically significant in both groups comparing with pre-treatment, however, no significant differences were found between the two groups. But there was significant difference in the increases of HDL-C between two groups. The efficacy-rates of Xuezhikang and Pravastatin were 54.6% and 68.4% for TC, 49.1% and 53.9% for HDL-C, 46.2% and 40.8% for TG respectively. There were no significant differences between the two groups. No severe side effects were observed in the two groups. Conclusion Low-dose statin drugs (such as Xuezhikang and Pravastatin) administrated in relatively long-term are effective and safe for Chinese patients with dyslipidemia.更多还原